A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
NCT04259281
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
74
Enrollment
INDUSTRY
Sponsor class
Conditions
Angelman Syndrome
Interventions
DRUG:
GTX-102
Sponsor
Ultragenyx Pharmaceutical Inc